Rigel Pharmaceuticals, Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: Election of Directors: Alison Hannah, M.D.

Rigel Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Alison Hannah, M.D.”): 9,202,113 for, 1,469,709 withheld, per its Form 8-K filed May 20, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors Each of the nominees for director, to serve until the Company's 2029 Annual Meeting of Stockholders or until his or her respective successor has been elected and qualified, was elected as follows:”
Support: 86% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 73 asset managers below reported 4,268,323 for, 436,903 against, 4,145 abstained.

Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.

Description as filed by funds: Election of Directors: Raul Rodriguez

Rigel Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Raul Rodriguez”): 10,486,503 for, 192,614 withheld, per its Form 8-K filed May 20, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors Each of the nominees for director, to serve until the Company's 2029 Annual Meeting of Stockholders or until his or her respective successor has been elected and qualified, was elected as follows:”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 73 asset managers below reported 4,695,623 for, 9,604 against, 4,145 abstained.

Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.

Description as filed by funds: Election of Directors: Walter Moos, Ph.D.

Rigel Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Walter Moos, Ph.D.”): 10,436,673 for, 242,736 withheld, per its Form 8-K filed May 20, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors Each of the nominees for director, to serve until the Company's 2029 Annual Meeting of Stockholders or until his or her respective successor has been elected and qualified, was elected as follows:”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 73 asset managers below reported 4,693,356 for, 10,951 against, 921 withheld, 4,145 abstained.

Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.

Description as filed by funds: To approve an amendment to our 2000 Employee Stock Purchase Plan, as amended (the "Amended 2000 ESPP"), to, among other things, add an additional 360,000 shares to the number of shares of common stock authorized for issuance under the Amended 2000 ESPP.

Rigel Pharmaceuticals, Inc.’s own tally for this item (“Approval of the 2000 Employee Stock Purchase Plan The Company's stockholders approved the Amended 2000 Employee Stock Purchase Plan.”): 9,840,922 for, 475,464 against — passed, per its Form 8-K filed May 20, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Approval of the 2000 Employee Stock Purchase Plan The Company's stockholders approved the Amended 2000 Employee Stock Purchase Plan.”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of Rigel Pharmaceuticals, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Amend Omnibus Stock Plan” (2 managers, 4,483 for, 17,317 against).

The 73 asset managers below reported 4,672,283 for, 37,088 against, 1 abstained.

Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.

Description as filed by funds: To approve an amendment to our 2018 Equity Incentive Plan, as amended (the "Amended 2018 Plan"), to add an additional 500,000 shares to the number of shares of common stock authorized for issuance under the Amended 2018 Plan.

Rigel Pharmaceuticals, Inc.’s own tally for this item (“Approval of the Amended 2018 Equity Incentive Plan The Company's stockholders approved the Amended 2018 Equity Incentive Plan.”): 6,497,964 for, 3,813,701 against — passed, per its Form 8-K filed May 20, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Approval of the Amended 2018 Equity Incentive Plan The Company's stockholders approved the Amended 2018 Equity Incentive Plan.”
Support: 63% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 71 asset managers below reported 3,344,179 for, 1,339,248 against, 4,146 abstained.

Showing the 25 largest of 71 asset managers. See all 71 in the interactive database.

Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the accompanying proxy statement.

Rigel Pharmaceuticals, Inc.’s own tally for this item (“Say-on-Pay The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.”): 9,013,480 for, 1,291,609 against — passed, per its Form 8-K filed May 20, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Say-on-Pay The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.”
Support: 87% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 71 managers: 4,185,625 for, 519,363 against, 4,146 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 160 managers: 6,146,555 for, 699,262 against, 5,157 not voted. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To ratify the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026.

The 71 asset managers below reported 4,266,133 for, 417,293 against, 4,145 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Showing the 25 largest of 71 asset managers. See all 71 in the interactive database.